FOLH1 and neoplasm: In a recent clinical study Kunikowska et al. [12] postulated a potential unsuitability of PSMA-11-based targeted therapies in recurrent GBM patients, due to the low median [68Ga]Ga-PSMA-11 tumour-to-liver ratio (TLR) observed in their patient cohort (i.e., 0.8, range: 0.6–1.8, N = 15).